Table 3 Standard incidence ratios (SIR) with 95% confidence intervals (CI) for a second malignancy by cancer site in men and women with a history of cutaneous malignant melanoma (CMM), adjusted for age and calendar period
From: New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway
|  |  | Women (N = 15 1841) | Men (N = 12 9721) | ||
|---|---|---|---|---|---|
ICD-10 | Cancer site2 | O3 | SIR (95% CI) | O3 | SIR (95% CI) |
C00-14 | Mouth, pharynx | 14 | 0.77 (0.46,1.30) | 33 | 1.11 (0.79,1.56) |
C18 | Colon | 163 | 1.02 (0.88,1.19) | 134 | 1.16 (0.98,1.37) |
C19-21 | Rectum | 57 | 0.87 (0.67,1.13) | 62 | 0.93 (0.72,1.19) |
C25 | Pancreas | 46 | 1.00 (0.76,1.33) | 39 | 1.06 (0.77,1.45) |
C33,34,38 | Lung | 109 | 1.12 (0.93,1.35) | 119 | 0.72 (0.60,0.87) |
C50 | Breast | 377 | 1.24 (1.12,1.37) | - | - |
C50-58 | Female organs | 588 | 1.18 (1.09,1.28) | - | - |
C61 | Prostate | - | - | 445 | 1.26 (1.15,1.38) |
C64-68 | Urinary organs | 68 | 0.93 (0.73,1.18) | 139 | 0.99 (0.84,1.17) |
C70-72 | CNS4 | 70 | 1.39 (1.09,1.75) | 41 | 1.31 (0.98,1.78) |
C73 | Thyroid | 19 | 1.27 (0.81,1.99) | 13 | 2.78 (1.61,4.80) |
C81-85 | Lymphoma | 56 | 1.29 (0.99,1.68) | 60 | 1.56 (1.20,1.99) |
C91-95 | Leukemia | 72 | 1.28 (1.01,1.60) | 64 | 1.22 (0.87,1.43) |
C00-965 | Other sites | 169 | 1.15 (0.99,1.34) | 176 | 1.07 (0.92,1.24) |
C43 | CMM | 438 | 7.59 (6.91,8.33) | 411 | 9.44 (8.57,10.4) |
C44 | SCC | 197 | 3.12 (2.71,3.59) | 204 | 3.11 (2.71,3.56) |
C00-96 | All sites | 2066 | 1.52 (1.46,1.59) | 1943 | 1.49 (1.43,1.60) |
C00-966 | All, exc. skin | 1431 | 1.16 (1.11,1.23) | 1328 | 1.12 (1.06,1.18) |
C00-967 | All, exc. CMM | 1628 | 1.26 (1.20,1.32) | 1532 | 1.25 (1.19,1.31) |